BeiGene Ltd ADR (BGNE)

HEALTH CARE: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS

C/O MOURANT GOVERNANCE SERVICES (CAYMAN) GRAND CAYMAN, CAYMAN ISLANDS KY1-1108

BeiGene, Ltd. operates as a clinical-stage biopharmaceutical company. The Company focuses on discovery and development of immuno-oncology drugs that address severe unmet medical needs in a variety of cancer indications. BeiGene serves patients worldwide.

Data based on most recent fiscal year report
Market Cap10.362 Billion Shares Outstanding61.07 Million Avg Volume449.914 Thousand
1-Yr BETA vs S&P TR1.508 Current Ratio7.89 Quick Ratio7.82
View SEC Filings from BGNE instead.

View recent insider trading info

Funds Holding BGNE (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding BGNE BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

65.3 Thousand total shares from 17 transactions

Exercise Derivative Conversion (M)

3 Thousand total shares from 2 transactions

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

HUANG JANE CMO, HEMATOLOGY

  • Officer
291,667 2020-01-21 12

AMGEN INC

  • 10% Owner
206,635,013 2020-01-02 1

HOOPER ANTHONY C

  • Director
0 2020-01-02 1

BAKER BROS. ADVISORS LP

667, L.P.

BAKER BROS. ADVISORS (GP) LLC

BAKER BROTHERS LIFE SCIENCES LP

BAKER FELIX

BAKER JULIAN

  • Director
  • 10% Owner
32,712,652 2019-12-31 1

OYLER JOHN CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
63,696,318 2019-12-17 5

GLAZER DONALD W.

  • Director
3,630,366 2019-11-20 5

LIANG HOWARD CFO & CHIEF STRATEGY OFFICER

  • Officer
122,317 2019-11-18 5

WU XIAOBIN PRESIDENT & GM CHINA

  • Officer
1,483,956 2019-11-15 4

WANG XIAODONG

  • Director
  • CHAIR, SCIENTIFIC ADVISORY BRD
7,684,952 2019-11-13 6

CHEN TIMOTHY YUNG-CHENG

  • Director
200 2019-11-04 3

PETERSON AMY C. EVP, CHIEF DEVELOPMENT OFFICER

  • Officer
0 2019-10-15 0

MALLEY THOMAS

  • Director
0 2019-06-25 1

YI QINGQING

  • Director
0 2019-06-17 2

BAKER BROS. ADVISORS LP

14159, L.P.

667, L.P.

BAKER BROS. ADVISORS (GP) LLC

BAKER BROTHERS LIFE SCIENCES LP

BAKER FELIX

BAKER JULIAN

  • Director
  • 10% Owner
32,431,899 2019-06-06 1

SU JINGSHYH S

  • Director
0 2019-06-05 1

LI JI EVP AND GL. HEAD OF BUS. DEV.

  • Officer
475,000 2018-02-28 0

HILLHOUSE CAPITAL MANAGEMENT, LTD.

  • 10% Owner
71,139,367 2018-01-22 0

TANG KE

  • Director
0 2017-04-19 0

YANG JIANXIN SR. VP, HEAD OF CLINICAL DEV.

  • Officer
0 2016-07-13 0

YAN WENDY XIAOJUN SR. VP, HEAD OF REG. AFFAIRS

  • Officer
0 2016-07-13 0

MERCK & CO., INC.

MERCK SHARP & DOHME CORP.

MERCK SHARP & DOHME RESEARCH GMBH

  • 10% Owner
31,589,038 2016-02-08 0

CB BIOTECH INVESTMENT LTD

CPECHINA FUND, L.P.

CITIC PE ASSOCIATES, L.P.

CITIC PE FUNDS LTD

  • 10% Owner
No longer subject to file 2016-02-08 0

YUAN RUIRONG CHIEF MEDICAL OFFICER

  • Officer
130,000 2016-02-08 0

KRISHANA RANJEEV

  • Director
0 2016-02-02 0

GOLLER MICHAEL

  • Director
0 2016-02-02 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5

HUANG JANE - Officer CMO, HEMATOLOGY

2020-01-21 M 19,500 d 558,575 291,667.00 direct

HUANG JANE - Officer CMO, HEMATOLOGY

2020-01-21 S 813 $170.10 d 687 291,667.00 direct yes

HUANG JANE - Officer CMO, HEMATOLOGY

2020-01-21 S 87 $172.34 d 0 291,667.00 direct yes

HUANG JANE - Officer CMO, HEMATOLOGY

2020-01-21 M 1,500 $29.49 a 1,500 291,667.00 direct

HUANG JANE - Officer CMO, HEMATOLOGY

2020-01-21 S 600 $171.27 d 87 291,667.00 direct yes

OYLER JOHN - Director - Officer CHIEF EXECUTIVE OFFICER

2019-12-17 S 200 $163.20 d 1,958 63,696,318.00 direct yes

OYLER JOHN - Director - Officer CHIEF EXECUTIVE OFFICER

2019-12-17 S 16,965 $160.60 d 22,773 63,696,318.00 direct yes

OYLER JOHN - Director - Officer CHIEF EXECUTIVE OFFICER

2019-12-17 S 2,400 $162.42 d 2,158 63,696,318.00 direct yes

OYLER JOHN - Director - Officer CHIEF EXECUTIVE OFFICER

2019-12-17 S 15,466 $159.59 d 39,738 63,696,318.00 direct yes

OYLER JOHN - Director - Officer CHIEF EXECUTIVE OFFICER

2019-12-17 S 1,958 $165.61 d 0 63,696,318.00 direct yes

OYLER JOHN - Director - Officer CHIEF EXECUTIVE OFFICER

2019-12-17 S 18,215 $161.49 d 4,558 63,696,318.00 direct yes

OYLER JOHN - Director - Officer CHIEF EXECUTIVE OFFICER

2019-12-17 S 7,055 $158.63 d 55,204 63,696,318.00 direct yes

HUANG JANE - Officer CMO, HEMATOLOGY

2019-12-16 M 1,500 $29.49 a 1,500 291,667.00 direct

HUANG JANE - Officer CMO, HEMATOLOGY

2019-12-16 M 19,500 d 578,075 291,667.00 direct

HUANG JANE - Officer CMO, HEMATOLOGY

2019-12-16 S 200 $170.73 d 200 291,667.00 direct yes

HUANG JANE - Officer CMO, HEMATOLOGY

2019-12-16 S 800 $161.93 d 600 291,667.00 direct yes

HUANG JANE - Officer CMO, HEMATOLOGY

2019-12-16 S 100 $173.59 d 0 291,667.00 direct yes

HUANG JANE - Officer CMO, HEMATOLOGY

2019-12-16 S 100 $168.90 d 400 291,667.00 direct yes

HUANG JANE - Officer CMO, HEMATOLOGY

2019-12-16 S 100 $160.07 d 1,400 291,667.00 direct yes

HUANG JANE - Officer CMO, HEMATOLOGY

2019-12-16 S 100 $172.13 d 100 291,667.00 direct yes

HUANG JANE - Officer CMO, HEMATOLOGY

2019-12-16 S 100 $165.55 d 500 291,667.00 direct yes
Click here to report any possible errors with this stock listing.

Elevate your investments